Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLA-DRB1 | P01911 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 11/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 6/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 8/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21110340 | 1.00 | HLA-DRB1 (0.55) | HLA-DRB1CTSKPSMB5CTSSCTSB | |
| SCHEMBL21110146 | 1.00 | HLA-DRB1 (0.55) | HLA-DRB1CTSKPSMB5CTSSCTSB | |
| SCHEMBL19345771 | 1.00 | HLA-DRB1 (0.55) | HLA-DRB1CTSKPSMB5CTSSCTSB | |
| SCHEMBL19345839 | 1.00 | HLA-DRB1 (0.55) | HLA-DRB1CTSKPSMB5CTSSCTSB | |
| SCHEMBL19345910 | 1.00 | HLA-DRB1 (0.55) | HLA-DRB1CTSKPSMB5CTSSCTSB | |
| SCHEMBL21109500 | 1.00 | HLA-DRB1 (0.55) | HLA-DRB1CTSKPSMB5CTSSCTSB | |
| SCHEMBL21110564 | 0.99 | HLA-DRB1 (0.55) | HLA-DRB1CTSKPSMB5CTSSCTSB | |
| SCHEMBL21110164 | 0.98 | HLA-DRB1 (0.57) | HLA-DRB1CTSKPSMB5CTSSCTSB | |
| SCHEMBL21109280 | 0.96 | CTSK (0.55) | HLA-DRB1CTSKPSMB5CTSSCTSB | |
| SCHEMBL19345743 | 0.96 | CTSK (0.55) | HLA-DRB1CTSKPSMB5CTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | BLADE THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | BLADE THERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017156071-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | BLADE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | CAPN1, CAPN9, CAPN2 | HLA-DRB1 4722/4885CTSK 566/4885PSMB5 410/4885 |
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | CAPN1, CAPN9, CAPN2 | HLA-DRB1 4722/4885CTSK 566/4885PSMB5 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.